臺灣博碩士論文加值系統

B型肝炎病毒感染所造成的疾病是全球性的重要問題。在全民預防接種計畫實施後，台灣民眾的B型肝炎表面抗原陽性率及相關疾病發生率已明顯下降。預防注射可減少，但無法完全根除B型肝炎病毒的傳染。曾接受預防注射卻仍感染到B型肝炎病毒者，最主要的感染源是母子傳染。台灣地區的B型肝炎病毒以基因型B和C為主，兩者相比，基因型C的感染者的臨床病程較嚴重。本研究的第一部分是：比較調查在預防接種實施前後，台灣B型肝炎帶原兒童的病毒基因型分布是否改變。本研究的第二部分則是一項前瞻性的B型肝炎帶原母親及其子女的追蹤研究，希望了解在現行預防措施下，B型肝炎病毒母子傳染的發生率及危險因子。
在研究的第一部分，我們收集了107位曾接受過完整B型肝炎預防注射，卻仍得到慢性B型肝炎病毒感染的兒童，稱之為「接受過預防注射的B型肝炎病毒感染者」。每一位「接受過預防注射的B型肝炎病毒感染者」會配上兩位在收案時年齡相仿的「未接種過預防注射的對照者」（214位對照者）。B型肝炎病毒基因型由分子學方法測定。和「未接種過預防注射的對照者」相比，「接受過預防注射的B肝病毒感染者」的母親B肝表面抗原陽性率明顯較高 (65.9% 比 100%, P值 < 0.001)，且感染基因型C的人也較多 (16.4% 比 42.1%, P值 < 0.001)。若這些兒童的母親也是B肝帶原者的話，母親和小孩的B肝病毒基因型非常一致，無論是「未接種過預防注射的對照者」(kappa值= 0.97, 95%信賴區間=0.90-1.00)，或「接受過預防注射的B型肝炎病毒感染者」(kappa值= 0.97, 95%信賴區間=0.92-1.00) 都是如此。在控制了小孩性別、母親生產時年齡、生產方式是否為剖腹等因素後，母親為B肝帶原者的「接受過預防注射的B型肝炎病毒感染者」比「未接種過預防注射的對照者」感染基因型C的可能性更高 (勝算比 = 3.03, 95%信賴區間：1.62-5.65, P = 0.001)。
在研究的第二部分，我們收集了303位B型肝炎帶原母親的孩子。小孩按現行預防接種規定接受疫苗（及免疫球蛋白）注射。母親的B型肝炎病毒濃度以即時聚合酶鏈鎖反應的方法測定。小孩在4-8個月大及/或1-3歲時接受B型肝炎表面抗原檢驗。我們用一多變項迴歸模式來預測小孩感染B型肝炎病毒的機率。和e抗原陰性的母親相比，e抗原陽性母親 (81/303, 26.7%) 的B型肝炎病毒濃度較高 (2.7 ± 1.4 versus 7.4 ± 1.9 log10 copies/ml, P < 0.0001)。有10個孩子成為慢性B型肝炎帶原，這10個孩子的母親均為e抗原陽性，且母親有高濃度的B型肝炎病毒量 (中位數：8.4；範圍：6.5-9.5 log10 copies/ml)。在控制母親生產時年齡、是否為剖腹產、是否有增加母子間出血的危險因子、懷孕週數、小孩性別、小孩出生體重、B型肝炎疫苗注射時間、是否餵食母奶等項目後，母親的病毒濃度量是小孩得到B型肝炎病毒感染的顯著危險因子（每升高一個log10 copies/ml，勝算比：3.49，95%信賴區間：1.63-7.48；P = 0.001）。當母親的病毒濃度在7、8、9 log10 copies/ml時，她的小孩得到B肝病毒感染的預測機率分別為：6.6% (95%信賴區間：0.5-12.6%；P = 0.033)、14.6% (95%信賴區間：5.6-23.6%；P = 0.001)、27.7% (95%信賴區間：13.1-42.4%；P < 0.001)。
總結來說，基因型B及基因型C的B型肝炎病毒兩者均可以經由母子傳染及水平傳染的方式傳播。母子傳染是接種疫苗兒童感染B型肝炎病毒的最主要感染途徑。和「未接種過預防注射的對照者」相比，在「接受過預防注射的B型肝炎病毒感染兒童」中，感染基因型C的比例變高了。這些兒童需要更謹慎的追蹤和醫療照護。其次，母親的病毒濃度量是導致B型肝炎病毒母子傳染的最重要因素。在現行的預防接種措施外，應考慮給予病毒濃度大於10^7-10^8 copies/ml的母親治療，以進一步減少B型肝炎病毒之母子傳染。

Hepatitis B virus (HBV) infection is a serious health problem worldwide. Since the launch of the universal immunization program, the seropositive rate of hepatitis B surface antigen (HBsAg) and the incidence rates of related complications in Taiwanese people have declined substantially. Immunoprophylaxis reduces but does not completely eradicate HBV transmission. Mother-to-infant transmission causes the majority of cases with immunoprophylactic failure. Genotypes B and C are the major HBV genotypes in Taiwan, and genotype C is associated with more severe liver disease than genotype B. The first part of the study aimed at investigating the HBV genotypes in HBsAg carrier children born before and after the implementation of the universal immunization program. The second part of the study was a prospective study to assess the rate and risk factors of maternally transmitted HBV infection in a cohort of HBV-infected women and their children.
In the first part of the study, 107 HBV-infected children despite appropriate immunization were enrolled as the immunized cases with HBV infection. Each case was matched with two un-immunized HBsAg carriers based on the age at enrollment. HBV genotypes were determined using molecular methods. Compared with un-immunized HBsAg carriers, more immunized children had HBsAg-positive mothers (65.9% versus 100%; P < 0.001), and were infected with genotype C (16.4% versus 42.1%; P < 0.001). Among the children born to HBsAg-positive mothers, maternal and children’s HBV genotypes were highly concordant in both un-immunized (kappa, 0.97; 95% confidence interval [CI], 0.90-1.00) and immunized children (kappa, 0.97; 95% CI, 0.92-1.00). After adjustment for gender, maternal age, and delivery mode, immunized HBsAg carrier children born to HBsAg-positive mothers had a higher likelihood of genotype C infection than un-immunized children (odds ratio, 3.03; 95% CI, 1.62-5.65; P = 0.001).
In the second part of the study, we enrolled 303 mother-infant pairs with positive maternal HBsAg under current immunization program. Maternal viral load was determined by a real-time PCR-based assay. The children were tested for HBsAg at 4-8 months and/or 1-3 years of age. Rates of HBV infection were estimated using a multivariate logistic regression model. Hepatitis B e antigen (HBeAg)-positive mothers (81/303, 26.7%) had higher viral loads than HBeAg-negative mothers (7.4 ± 1.9 versus 2.7 ± 1.4 log10 copies/ml, P < 0.0001). Ten children, born to HBeAg-positive mothers with high viral load (median, 8.4; range, 6.5-9.5 log10 copies/ml), were chronically infected. After adjustment for maternal age, birth type, factors related to maternal-fetal hemorrhage, gestational age, infant gender, birth weight, timeliness of vaccination, and feeding practice, maternal viral load was significantly associated with the risk of infection (adjusted odds ratio for each log10 copy/ml increase, 3.49; 95% CI, 1.63-7.48; P = 0.001). The predictive rates of infection at maternal viral load levels of 7, 8, and 9 log10 copies/ml were 6.6% (95% CI, 0.5-12.6%; P = 0.033), 14.6% (95% CI, 5.6- 23.6%; P = 0.001), and 27.7% (95% CI, 13.1-42.4%; P < 0.001), respectively.
In summary, both HBV genotypes B and C can be transmitted from maternal and horizontal origins and maternal transmission is responsible for most HBV infections in children with immunoprophylactic failure. Compared with un-immunized HBsAg carriers, more immunized children had genotype C infection. These children need more careful long-term follow-up. Second, maternal HBV DNA level is the most important risk factor causing maternally transmitted HBV infection. Additional strategies to further reduce transmission should be considered in mothers with a viral load above 10^7-10^8 copies/ml.

一、緒論
1.1 B型肝炎病毒感染 …………………………………………………………… 1
1.2 B型肝炎疫苗接種計畫 ……………………………………………………… 3
1.3 接種B型肝炎疫苗兒童發生B型肝炎病毒感染 …………………………… 7
1.4 接種疫苗兒童發生B型肝炎病毒感染之原因 ……………………………… 9
1.4.1 子宮內感染 ………………………………………………………………… 9
1.4.2 高濃度的母親B型肝炎病毒量 …………………………………………… 11
1.4.3 表面基因突變的B型肝炎病毒感染 ……………………………………… 16
1.4.4 人體因素無法對B型肝炎疫苗產生抗體 ………………………………… 20
1.5 B型肝炎病毒基因型 ………………………………………………………… 21
1.6 研究目的及假說 …………………………………………………………… 23
1.6.1 預防注射後B型肝炎帶原兒童病毒基因型分布之變化 ………………… 23
1.6.2 B型肝炎病毒母子傳染的前瞻性研究 …………………………………… 24

二、研究方法與材料
2.1 研究對象 …………………………………………………………………… 25
2.1.1 預防注射後B型肝炎帶原兒童病毒基因型分布之變化 ………………… 25
2.1.2 B型肝炎病毒母子傳染的前瞻性研究 …………………………………… 26
2.2 研究方法 …………………………………………………………………… 27
2.2.1 B型肝炎病毒血清學標記 ………………………………………………… 27
2.2.2 B型肝炎病毒基因型鑑定 ………………………………………………… 27
2.2.3 B型肝炎病毒量測定 ……………………………………………………… 30
2.3 統計方法 …………………………………………………………………… 30

三、結果
3.1 預防注射後B型肝炎帶原兒童病毒基因型分布之變化 …………………… 33
3.1.1 B型肝炎帶原兒童之臨床資料 …………………………………………… 33
3.1.2 B肝帶原兒童病毒基因型分布和預防注射及母親B肝帶原的關係 …… 33
3.1.3 B型肝炎帶原兒童和其母親的B型肝炎病毒基因型比較 ……………… 34
3.1.4 B型肝炎病毒基因型分布的長期趨勢 …………………………………… 35
3.1.5 預防接種對B型肝炎病毒基因型分布的影響 …………………………… 36
3.2 B型肝炎病毒母子傳染的前瞻性研究 ……………………………………… 36
3.2.1 B型肝炎帶原母親的臨床資料 …………………………………………… 37
3.2.2 小孩的預防注射及追蹤 …………………………………………………… 38
3.2.3 B型肝炎病毒母子傳染的個案 …………………………………………… 39
3.2.4 B型肝炎病毒母子傳染的危險因子 ……………………………………… 39
3.2.5 B型肝炎病毒母子傳染的預測發生率 …………………………………… 40

四、討論
4.1 預防注射實施前後B型肝炎帶原兒童的感染途徑 ………………………… 41
4.2 B型肝炎病毒基因型分布的長期趨勢及和預防接種的關係 ……………… 45
4.3 B型肝炎病毒基因型和e抗原及病毒濃度的關係 ………………………… 48
4.4 B型肝炎病毒母子傳染的危險因子 ………………………………………… 53
4.5 進一步防止B型肝炎病毒母子傳染的策略 ………………………………… 56

五、展望 ………………………………………………………………………… 60

六、論文英文簡述
Introduction …………………………………………………………………… 66
Subjects………………………………………………………………………… 68
I. HBV genotype distribution after universal infant immunization ………… 68
II. Prospective study of mother-to-infant transmission of HBV infection … 69
Methods ………………………………………………………………………… 70
HBV serology …………………………………………………………………… 70
HBV genotyping ………………………………………………………………… 71
HBV DNA quantification ……………………………………………………… 71
Statistical analyses …………………………………………………………… 72
Results ………………………………………………………………………… 73
I. HBV genotype distribution after universal infant immunization ………… 73
II. Prospective study of mother-to-infant transmission of HBV infection … 75
Discussion ……………………………………………………………………… 78

七、參考文獻 …………………………………………………………………… 83

八、圖示
圖1. 預防注射後B型肝炎帶原兒童病毒基因型分布變化之分組流程圖 …… 104
圖2. B型肝炎帶原母親及其子女收案追蹤流程圖 …………………………… 105
圖3. B肝帶原兒童病毒基因型分布和預防注射及母親B肝帶原的關係 …… 106
圖4. B肝帶原兒童病毒基因型分布和預防注射及出生年分的關係 ………… 107
圖5. 母親的B型肝炎病毒濃度分布和e抗原的關係 ………………………… 108
圖6. B型肝炎病毒母子傳染的預測發生率 …………………………………… 109

九、表格
表1. B型肝炎帶原兒童之臨床資料 …………………………………………… 110
表2. B型肝炎帶原兒童和其母親的B型肝炎病毒基因型比較 ……………… 111
表3. 母親為B肝帶原者的不同基因型B肝病毒感染兒童之比較 …………… 112
表4. 母親為B肝帶原的兒童感染B肝病毒基因型C之多變項迴歸分析 …… 113
表5. B肝帶原母親的小孩，接受和未接受B肝表面抗原檢驗者之比較 …… 114
表6. B型肝炎帶原母親的臨床資料 …………………………………………… 115
表7. B型肝炎病毒母子傳染的個案及其母親的資料 ………………………… 116
表8. B型肝炎病毒母子傳染相關因素之單變項及多變項迴歸分析 ………… 117

十、附錄 ………………………………………………………………………… 118

American Academy of Pediatrics. Preterm and Low Birth Weight Infants. In: LK Pickering, editor. Red Book: 2009 Report of the Committee on Infectious Diseases, 28th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2009.
Arauz-Ruiz P, Norder H, Robertson BH and Magnius LO. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. J Gen Virol. 2002;83(8):2059-2073.
Bartholomeusz A and Schaefer S. Hepatitis B virus genotypes: comparison of genotyping methods. Rev Med Virol. 2004;14(1):3-16.
Basuni AA, Butterworth L, Cooksley G, Locarnini S and Carman WF. Prevalence of HBsAg mutants and impact of hepatitis B infant immunisation in four Pacific Island countries. Vaccine. 2004;22(21-22):2791-2799.
Beasley RP and Hwang LY. Postnatal infectivity of hepatitis B surface antigen-carrier mothers. J Infect Dis. 1983;147(2):185-190.
Beasley RP, Hwang LY, Lee GC, Lan CC, Roan CH, Huang FY and Chen CL. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet. 1983;2(8359):1099-1102.
Bzowej NH. Hepatitis B Therapy in Pregnancy. Curr Hepat Rep. 2010;9(4):197-204.
Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, Zuckerman AJ and Thomas HC. Vaccine-induced escape mutant of hepatitis B virus. Lancet. 1990;336(8711):325-329.
Carman WF, Van Deursen FJ, Mimms LT, Hardie D, Coppola R, Decker R and Sanders R. The prevalence of surface antigen variants of hepatitis B virus in Papua New Guinea, South Africa, and Sardinia. Hepatology. 1997;26(6):1658-1666.
Centers for Disease Control [Taiwan]. Guidelines for treating persons receiving a complete course of hepatitis B vaccine but negative for antibodies to hepatitis B surface antigen. Retrieved April, 2013, from http://www.cdc.gov.tw/professional/page.aspx?treeid=5B0231BEB94EDFFC&nowtreeid=F93FD1BEB174A264.
Centers for Disease Control [Taiwan]. Revision to the administration time of the first dose of hepatitis B vaccine. Retrieved November, 2011, from http://www.pediatr.org.tw/DB/News/file/1065-1.pdf.
Centers for Disease Control [Taiwan]. Recommendations for immunoprophylaxis of low-birth-weight newborns with hepatitis B e antigen-positive mothers. Retrieved June, 2013, from http://www.pediatr.org.tw/db/paper/588/588_1.pdf.
Chan CY, Lee SD, Tsai YT and Lo KJ. Booster response to recombinant yeast-derived hepatitis B vaccine in vaccinees whose anti-HBs responses were initially elicited by a plasma-derived vaccine. Vaccine. 1991;9(10):765-767.
Chan HL, Wong VW, Wong GL, Tse CH, Chan HY and Sung JJ. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology. 2010;52(4):1232-1241.
Chan HL, Thompson A, Martinot-Peignoux M, Piratvisuth T, Cornberg M, Brunetto MR, Tillmann HL, Kao JH, Jia JD, Wedemeyer H, Locarnini S, Janssen HL and Marcellin P. Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. J Hepatol. 2011;55(5):1121-1131.
Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY and Chen DS. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med. 1997;336(26):1855-1859.
Chang MH, Chen TH, Hsu HM, Wu TC, Kong MS, Liang DC, Ni YH, Chen CJ and Chen DS. Prevention of hepatocellular carcinoma by universal vaccination against hepatitis B virus: the effect and problems. Clin Cancer Res. 2005;11(21):7953-7957.
Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, Chu HC, Wu TC, Yang SS, Kuo HS and Chen DS. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst. 2009;101(19):1348-1355.
Chen DS and Sung JL. Hepatitis B virus infection on Taiwan. N Engl J Med. 1977;297(12):668-669.
Chen DS. Toward elimination and eradication of hepatitis B. J Gastroenterol Hepatol. 2010;25(1):19-25.
Chen HL, Chang MH, Ni YH, Hsu HY, Lee PI, Lee CY and Chen DS. Seroepidemiology of hepatitis B virus infection in children: Ten years of mass vaccination in Taiwan. JAMA. 1996;276(11):906-908.
Chen HL, Chang CJ, Kong MS, Huang FC, Lee HC, Lin CC, Liu CC, Lee IH, Wu TC, Wu SF, Ni YH, Hsu HY, Chen DS and Chang MH. Pediatric fulminant hepatic failure in endemic areas of hepatitis B infection: 15 years after universal hepatitis B vaccination. Hepatology. 2004;39(1):58-63.
Chen HL, Lin LH, Hu FC, Lee JT, Lin WT, Yang YJ, Huang FC, Wu SF, Chen SC, Wen WH, Chu CH, Ni YH, Hsu HY, Tsai PL, Chiang CL, Shyu MK, Lee PI, Chang FY and Chang MH. Effects of Maternal Screening and Universal Immunization to Prevent Mother-to-Infant Transmission of HBV. Gastroenterology. 2012;142(4):773-781 e772.
Chevaliez S, Rodriguez C and Pawlotsky JM. New virologic tools for management of chronic hepatitis B and C. Gastroenterology. 2012;142(6):1303-1313 e1301.
Chiou HL, Lee TS, Kuo J, Mau YC and Ho MS. Altered antigenicity of ''a'' determinant variants of hepatitis B virus. J Gen Virol. 1997;78 ( Pt 10):2639-2645.
Chu CJ, Hussain M and Lok AS. Quantitative Serum HBV DNA Levels During Different Stages of Chronic Hepatitis B Infection. Hepatology. 2002a;36(6):1408-1415.
Chu CJ, Hussain M and Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology. 2002b;122(7):1756-1762.
Cooreman MP, van Roosmalen MH, te Morsche R, Sunnen CM, de Ven EM, Jansen JB, Tytgat GN, de Wit PL and Paulij WP. Characterization of the reactivity pattern of murine monoclonal antibodies against wild-type hepatitis B surface antigen to G145R and other naturally occurring "a" loop escape mutations. Hepatology. 1999;30(5):1287-1292.
Cooreman MP, Leroux-Roels G and Paulij WP. Vaccine- and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen. J Biomed Sci. 2001;8(3):237-247.
De Silvestri A, Pasi A, Martinetti M, Belloni C, Tinelli C, Rondini G, Salvaneschi L and Cuccia M. Family study of non-responsiveness to hepatitis B vaccine confirms the importance of HLA class III C4A locus. Genes Immun. 2001;2(7):367-372.
del Canho R, Grosheide PM, Mazel JA, Heijtink RA, Hop WC, Gerards LJ, de Gast GC, Fetter WP, Zwijneberg J and Schalm SW. Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: protective efficacy and long-term immunogenicity. Vaccine. 1997;15(15):1624-1630.
Desombere I, Willems A and Leroux-Roels G. Response to hepatitis B vaccine: multiple HLA genes are involved. Tissue Antigens. 1998;51(6):593-604.
Elwood M. Critical Appraisal of Epidemiological Studies and Clinical Trials, 3rd ed. New York: Oxford University Press; 2007.
Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology. 2009;49(5 Suppl):S185-195.
Fried MW, Piratvisuth T, Lau GK, Marcellin P, Chow WC, Cooksley G, Luo KX, Paik SW, Liaw YF, Button P and Popescu M. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology. 2008;47(2):428-434.
Hadziyannis SJ and Papatheodoridis GV. Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. Semin Liver Dis. 2006;26(2):130-141.
Han G-R, Cao M-K, Zhao W, Jiang H-X, Wang C-M, Bai S-F, Yue X, Wang G-J, Tang X and Fang Z-X. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. Journal of Hepatology. 2011;55(6):1215-1221.
Hill JB, Sheffield JS, Kim MJ, Alexander JM, Sercely B and Wendel GD. Risk of hepatitis B transmission in breast-fed infants of chronic hepatitis B carriers. Obstet Gynecol. 2002;99(6):1049-1052.
Hilleman MR, Buynak EB, Roehm RR, Tytell AA, Bertland AU and Lampson GP. Purified and inactivated human hepatitis B vaccine: progress report. Am J Med Sci. 1975;270(2):401-404.
Hohler T, Reuss E, Evers N, Dietrich E, Rittner C, Freitag CM, Vollmar J, Schneider PM and Fimmers R. Differential genetic determination of immune responsiveness to hepatitis B surface antigen and to hepatitis A virus: a vaccination study in twins. Lancet. 2002;360(9338):991-995.
Hsu HM, Lu CF, Lee SC, Lin SR and Chen DS. Seroepidemiologic survey for hepatitis B virus infection in Taiwan: the effect of hepatitis B mass immunization. J Infect Dis. 1999;179(2):367-370.
Hsu HM, Lee SC, Wang MC, Lin SF and Chen DS. Efficacy of a mass hepatitis B immunization program after switching to recombinant hepatitis B vaccine: a population-based study in Taiwan. Vaccine. 2001;19(20-22):2825-2829.
Hsu HY, Chang MH, Chen DS, Lee CY and Sung JL. Baseline seroepidemiology of hepatitis B virus infection in children in Taipei, 1984: a study just before mass hepatitis B vaccination program in Taiwan. J Med Virol. 1986;18(4):301-307.
Hsu HY, Chang MH, Ho HN, Hsieh RP, Lee SD, Chen DS, Lee CY and Hsieh KH. Association of HLA-DR14-DR52 with low responsiveness to hepatitis B vaccine in Chinese residents in Taiwan. Vaccine. 1993;11(14):1437-1440.
Hsu HY, Chang MH, Ni YH, Lin HH, Wang SM and Chen DS. Surface gene mutants of hepatitis B virus in infants who develop acute or chronic infections despite immunoprophylaxis. Hepatology. 1997;26(3):786-791.
Hsu HY, Chang MH, Ni YH, Chiang CL, Chen HL, Wu JF and Chen PJ. No increase in prevalence of hepatitis B surface antigen mutant in a population of children and adolescents who were fully covered by universal infant immunization. J Infect Dis. 2010;201(8):1192-1200.
Inui A, Komatsu H, Sogo T, Nagai T, Abe K and Fujisawa T. Hepatitis B virus genotypes in children and adolescents in Japan: before and after immunization for the prevention of mother to infant transmission of hepatitis B virus. J Med Virol. 2007;79(6):670-675.
Jan CF, Huang KC, Chien YC, Greydanus DE, Davies HD, Chiu TY, Huang LM, Chen CJ and Chen DS. Determination of immune memory to hepatitis B vaccination through early booster response in college students. Hepatology. 2010;51(5):1547-1554.
Jaroszewicz J, Calle Serrano B, Wursthorn K, Deterding K, Schlue J, Raupach R, Flisiak R, Bock CT, Manns MP, Wedemeyer H and Cornberg M. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol. 2010;52(4):514-522.
Kao JH, Chen PJ, Lai MY and Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology. 2000;118(3):554-559.
Kao JH, Hsu HM, Shau WY, Chang MH and Chen DS. Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan. J Pediatr. 2001;139(3):349-352.
Kao JH, Chen PJ, Lai MY and Chen DS. Clinical and virological aspects of blood donors infected with hepatitis B virus genotypes B and C. J Clin Microbiol. 2002;40(1):22-25.
Kao JH and Chen DS. Clinical relevance of hepatitis B virus genotypes Ba and Bj in Taiwan. Gastroenterology. 2003;125(6):1916-1917; author reply 1917-1918.
Ko TM, Lin KH, Ho MM, Hwang MF, Hwang KC, Hsieh FJ, Yaung CL and Chen DS. Perinatal transmission of hepatitis B virus in the Taoyuan area. J Formos Med Assoc. 1986;85(4):341-351.
Kobayashi M, Suzuki F, Arase Y, Akuta N, Suzuki Y, Hosaka T, Saitoh S, Tsubota A, Someya T, Ikeda K, Matsuda M, Sato J and Kumada H. Infection with hepatitis B virus genotype A in Tokyo, Japan during 1976 through 2001. J Gastroenterol. 2004;39(9):844-850.
Krugman S and Giles JP. Viral hepatitis, type B (MS-2-strain). Further observations on natural history and prevention. N Engl J Med. 1973;288(15):755-760.
Kwon JH, Jang JW, Lee S, Lee J, Chung KW, Lee YS and Choi JY. Pretreatment HBeAg level and an early decrease in HBeAg level predict virologic response to entecavir treatment for HBeAg-positive chronic hepatitis B. J Viral Hepat. 2012;19(2):e41-47.
Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11(2):97-107.
Lee SD, Lo KJ, Wu JC, Tsai YT, Wang JY, Ting LP and Tong MJ. Prevention of maternal-infant hepatitis B virus transmission by immunization: the role of serum hepatitis B virus DNA. Hepatology. 1986;6(3):369-373.
Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337(24):1733-1745.
Li Y, Ni R, Song W, Shao W, Shrestha S, Ahmad S, Cunningham CK, Flynn PM, Kapogiannis BG, Wilson CM and Tang J. Clear and independent associations of several HLA-DRB1 alleles with differential antibody responses to hepatitis B vaccination in youth. Hum Genet. 2009;126(5):685-696.
Lin CL, Kao JH, Chen BF, Chen PJ, Lai MY and Chen DS. Application of hepatitis B virus genotyping and phylogenetic analysis in intrafamilial transmission of hepatitis B virus. Clin Infect Dis. 2005;41(11):1576-1581.
Lin CL and Kao JH. Hepatitis B viral factors and clinical outcomes of chronic hepatitis B. J Biomed Sci. 2008;15(2):137-145.
Lin HH, Lee TY, Chen DS, Sung JL, Ohto H, Etoh T, Kawana T and Mizuno M. Transplacental leakage of HBeAg-positive maternal blood as the most likely route in causing intrauterine infection with hepatitis B virus. J Pediatr. 1987;111(6 Pt 1):877-881.
Lin HH, Chang MH, Chen DS, Sung JL, Hong KH, Young YC, Yang KH and Lee TY. Early predictor of the efficacy of immunoprophylaxis against perinatal hepatitis B transmission: analysis of prophylaxis failure. Vaccine. 1991;9(6):457-460.
Lin HH, Kao JH, Chang TC, Hsu HY and Chen DS. Secular trend of age-specific prevalence of hepatitis B surface and e antigenemia in pregnant women in Taiwan. J Med Virol. 2003;69(4):466-470.
Liu CJ, Kao JH and Chen DS. Therapeutic implications of hepatitis B virus genotypes. Liver Int. 2005;25(6):1097-1107.
Livingston SE, Simonetti JP, Bulkow LR, Homan CE, Snowball MM, Cagle HH, Negus SE and McMahon BJ. Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology. 2007;133(5):1452-1457.
Lo KJ, Tsai YT, Lee SD, Wu TC, Wang JY, Chen GH, Yeh CL, Chiang BN, Yeh SH, Goudeau A and et al. Immunoprophylaxis of infection with hepatitis B virus in infants born to hepatitis B surface antigen-positive carrier mothers. J Infect Dis. 1985;152(4):817-822.
Lok AS. Chronic hepatitis B. N Engl J Med. 2002;346(22):1682-1683.
Losonsky GA, Wasserman SS, Stephens I, Mahoney F, Armstrong P, Gumpper K, Dulkerian S, West DJ and Gewolb IH. Hepatitis B vaccination of premature infants: a reassessment of current recommendations for delayed immunization. Pediatrics. 1999;103(2):E14.
Marion SA, Pastore MT, Pi DW and Mathias RG. Long-term Follow-up of Hepatitis B Vaccine in Infants of Carrier Mothers. American Journal of Epidemiology. 1994;140(8):734-746.
McMahon BJ. The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B. Hepatol Int. 2009;3(2):334-342.
Milich DR and Leroux-Roels GG. Immunogenetics of the response to HBsAg vaccination. Autoimmun Rev. 2003;2(5):248-257.
Moriya T, Kuramoto IK, Yoshizawa H and Holland PV. Distribution of hepatitis B virus genotypes among American blood donors determined with a PreS2 epitope enzyme-linked immunosorbent assay kit. J Clin Microbiol. 2002;40(3):877-880.
Naito H, Hayashi S and Abe K. Rapid and specific genotyping system for hepatitis B virus corresponding to six major genotypes by PCR using type-specific primers. J Clin Microbiol. 2001;39(1):362-364.
National Center for Biotechnology Information. BLAST. Basic Local Alignment Search Tool. Retrieved October, 2010, from http://blast.ncbi.nlm.nih.gov/Blast.cgi.
Nguyen T, Thompson AJ, Bowden S, Croagh C, Bell S, Desmond PV, Levy M and Locarnini SA. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol. 2010;52(4):508-513.
Ni YH, Chang MH, Huang LM, Chen HL, Hsu HY, Chiu TY, Tsai KS and Chen DS. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med. 2001;135(9):796-800.
Ni YH, Chang MH, Wang KJ, Hsu HY, Chen HL, Kao JH, Yeh SH, Jeng YM, Tsai KS and Chen DS. Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma. Gastroenterology. 2004;127(6):1733-1738.
Ni YH, Huang LM, Chang MH, Yen CJ, Lu CY, You SL, Kao JH, Lin YC, Chen HL, Hsu HY and Chen DS. Two decades of universal hepatitis B vaccination in Taiwan: impact and implication for future strategies. Gastroenterology. 2007;132(4):1287-1293.
Ni YH, Chang MH, Wu JF, Hsu HY, Chen HL and Chen DS. Minimization of hepatitis B infection by a 25-year universal vaccination program. J Hepatol. 2012;57(4):730-735.
Norder H, Courouce AM and Magnius LO. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology. 1994;198(2):489-503.
Okamoto H, Tsuda F, Sakugawa H, Sastrosoewignjo RI, Imai M, Miyakawa Y and Mayumi M. Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J Gen Virol. 1988;69:2575-2583.
Orito E, Mizokami M, Ina Y, Moriyama EN, Kameshima N, Yamamoto M and Gojobori T. Host-independent evolution and a genetic classification of the hepadnavirus family based on nucleotide sequences. Proc Natl Acad Sci U S A. 1989;86(18):7059-7062.
Orito E, Ichida T, Sakugawa H, Sata M, Horiike N, Hino K, Okita K, Okanoue T, Iino S, Tanaka E, Suzuki K, Watanabe H, Hige S and Mizokami M. Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology. 2001;34(3):590-594.
Pan CQ, Duan ZP, Bhamidimarri KR, Zou HB, Liang XF, Li J and Tong MJ. An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus. Clin Gastroenterol Hepatol. 2012a;10(5):452-459.
Pan CQ, Han GR, Jiang HX, Zhao W, Cao MK, Wang CM, Yue X and Wang GJ. Telbivudine Prevents Vertical Transmission From HBeAg-Positive Women With Chronic Hepatitis B. Clin Gastroenterol Hepatol. 2012b;10(5):520-526.
Pan CQ, Mi LJ, Bunchorntavakul C, Karsdon J, Huang WM, Singhvi G, Ghany MG and Reddy KR. Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series. Dig Dis Sci. 2012c;57(9):2423-2429.
Perrillo R, Mimms L, Schechtman K, Robbins D and Campbell C. Monitoring of antiviral therapy with quantitative evaluation of HBeAg: a comparison with HBV DNA testing. Hepatology. 1993;18(6):1306-1312.
Petersen J. HBV treatment and pregnancy. J Hepatol. 2011;55(6):1171-1173.
Petrova M and Kamburov V. Breastfeeding and chronic HBV infection: clinical and social implications. World J Gastroenterol. 2010;16(40):5042-5046.
Rozanov M, Plikat U, Chappey C, Kochergin A and Tatusova T. A web-based genotyping resource for viral sequences. Nucleic Acids Res. 2004;32(Web Server issue):W654-659.
Sakamoto T, Tanaka Y, Simonetti J, Osiowy C, Borresen ML, Koch A, Kurbanov F, Sugiyama M, Minuk GY, McMahon BJ, Joh T and Mizokami M. Classification of hepatitis B virus genotype B into 2 major types based on characterization of a novel subgenotype in Arctic indigenous populations. J Infect Dis. 2007;196(10):1487-1492.
Seto WK, Wong DK, Fung J, Huang FY, Lai CL and Yuen MF. Reduction of hepatitis B surface antigen levels and HBsAg seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. Hepatology. 2013.
Shao ZJ, Xu DZ, Xu JQ, Li JH, Yan YP, Men K, Wang XP, Zhang ZY, Jiang QW and Zhang L. Maternal hepatitis B virus (HBV) DNA positivity and sexual intercourse are associated with HBV intrauterine transmission in China: a prospective case-control study. J Gastroenterol Hepatol. 2007;22(2):165-170.
Shi Z, Li X, Ma L and Yang Y. Hepatitis B immunoglobulin injection in pregnancy to interrupt hepatitis B virus mother-to-child transmission-a meta-analysis. Int J Infect Dis. 2010;14(7):e622-634.
Singh AE, Plitt SS, Osiowy C, Surynicz K, Kouadjo E, Preiksaitis J and Lee B. Factors associated with vaccine failure and vertical transmission of hepatitis B among a cohort of Canadian mothers and infants. J Viral Hepat. 2011;18(7):468-473.
Stephenne J. Recombinant versus plasma-derived hepatitis B vaccines: issues of safety, immunogenicity and cost-effectiveness. Vaccine. 1988;6(4):299-303.
Stevens CE, Beasley RP, Tsui J and Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med. 1975;292(15):771-774.
Stevens CE, Neurath RA, Beasley RP and Szmuness W. HBeAg and anti-HBe detection by radioimmunoassay: correlation with vertical transmission of hepatitis B virus in Taiwan. J Med Virol. 1979;3(3):237-241.
Stirk HJ, Thornton JM and Howard CR. A topological model for hepatitis B surface antigen. Intervirology. 1992;33(3):148-158.
Stuyver L, De Gendt S, Van Geyt C, Zoulim F, Fried M, Schinazi RF and Rossau R. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol. 2000;81(Pt 1):67-74.
Sugauchi F, Orito E, Ichida T, Kato H, Sakugawa H, Kakumu S, Ishida T, Chutaputti A, Lai C-L, Gish RG, Ueda R, Miyakawa Y and Mizokami M. Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. Gastroenterology. 2003;124(4):925-932.
Sugiyama M, Tanaka Y, Kato T, Orito E, Ito K, Acharya SK, Gish RG, Kramvis A, Shimada T, Izumi N, Kaito M, Miyakawa Y and Mizokami M. Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens. Hepatology. 2006;44(4):915-924.
Sugiyama M, Tanaka Y, Kurbanov F, Maruyama I, Shimada T, Takahashi S, Shirai T, Hino K, Sakaida I and Mizokami M. Direct cytopathic effects of particular hepatitis B virus genotypes in severe combined immunodeficiency transgenic with urokinase-type plasminogen activator mouse with human hepatocytes. Gastroenterology. 2009;136(2):652-662 e653.
Tabor E. Infections by hepatitis B surface antigen gene mutants in Europe and North America. J Med Virol. 2006;78(S1):S43-S47.
Tang JR, Hsu HY, Lin HH, Ni YH and Chang MH. Hepatitis B surface antigenemia at birth: a long-term follow-up study. J Pediatr. 1998;133(3):374-377.
Thio CL, Thomas DL and Carrington M. Chronic viral hepatitis and the human genome. Hepatology. 2000;31(4):819-827.
Thompson AJ, Nguyen T, Iser D, Ayres A, Jackson K, Littlejohn M, Slavin J, Bowden S, Gane EJ, Abbott W, Lau GK, Lewin SR, Visvanathan K, Desmond PV and Locarnini SA. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology. 2010;51(6):1933-1944.
Tsai TY, Lo KJ and Lee SD. Immunoprophylaxis against hepatitis B virus infection: a controlled trial in infants born to HBeAg-negative HBsAg carrier mothers in Taiwan. Chin J Gasteroenterol. 1984;1(1):181-185.
Tsen YJ, Chang MH, Hsu HY, Lee CY, Sung JL and Chen DS. Seroprevalence of hepatitis B virus infection in children in Taipei, 1989: five years after a mass hepatitis B vaccination program. J Med Virol. 1991;34(2):96-99.
Tseng TC, Liu CJ, Su TH, Wang CC, Chen CL, Chen PJ, Chen DS and Kao JH. Serum Hepatitis B Surface Antigen Levels Predict Surface Antigen Loss in Hepatitis B e Antigen Seroconverters. Gastroenterology. 2011;141(2):517-525.e512.
Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, Kuo SF, Liu CH, Chen PJ, Chen DS and Kao JH. Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. Hepatology. 2012a;55(1):68-76.
Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, Kuo SF, Liu CH, Chen PJ, Chen DS and Kao JH. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology. 2012b;142(5):1140-1149 e1143.
Usuda S, Okamoto H, Iwanari H, Baba K, Tsuda F, Miyakawa Y and Mayumi M. Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product. J Virol Methods. 1999;80(1):97-112.
Wang Z, Zhang J, Yang H, Li X, Wen S, Guo Y, Sun J and Hou J. Quantitative analysis of HBV DNA level and HBeAg titer in hepatitis B surface antigen positive mothers and their babies: HBeAg passage through the placenta and the rate of decay in babies. J Med Virol. 2003;71(3):360-366.
Watanabe K, Takahashi T, Takahashi S, Okoshi S, Ichida T and Aoyagi Y. Comparative study of genotype B and C hepatitis B virus-induced chronic hepatitis in relation to the basic core promoter and precore mutations. J Gastroenterol Hepatol. 2005;20(3):441-449.
Wiseman E, Fraser MA, Holden S, Glass A, Kidson BL, Heron LG, Maley MW, Ayres A, Locarnini SA and Levy MT. Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust. 2009;190(9):489-492.
World Health Organization. Hepatitis B vaccines: WHO position paper. Weekly Epidemiological Record 2009;84(40):405-420.
Xu DZ, Yan YP, Choi BCK, Xu JQ, Men K, Zhang JX, Liu ZH and Wang FS. Risk factors and mechanism of transplacental transmission of hepatitis B virus: A case-control study. J Med Virol. 2002;67(1):20-26.
Xu WM, Cui YT, Wang L, Yang H, Liang ZQ, Li XM, Zhang SL, Qiao FY, Campbell F, Chang CN, Gardner S and Atkins M. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat. 2009;16(2):94-103.
Xu YY, Yu JY, Zhong YW, Song HB, Liu HH, Jia LL, Li SL, Xu JQ and Li Q. Association between the frequency of class II HLA antigens and the susceptibility to intrauterine infection of hepatitis B virus. Int J Biol Sci. 2008;4(2):111-115.
Yang J, Zeng XM, Men YL and Zhao LS. Elective caesarean section versus vaginal delivery for preventing mother to child transmission of hepatitis B virus--a systematic review. Virol J. 2008;5:100.
Yeh SH, Tsai CY, Kao JH, Liu CJ, Kuo TJ, Lin MW, Huang WL, Lu SF, Jih J, Chen DS and Chen PJ. Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. J Hepatol. 2004;41(4):659-666.
Yu MW, Yeh SH, Chen PJ, Liaw YF, Lin CL, Liu CJ, Shih WL, Kao JH, Chen DS and Chen CJ. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst. 2005;97(4):265-272.
Zhang X, Lin SM, Ye F, Chen TY, Liu M, Chen YR, Zheng SQ, Zhao YR and Zhang SL. An early decrease in serum HBeAg titre is a strong predictor of virological response to entecavir in HBeAg-positive patients. J Viral Hepat. 2011;18(7):e184-190.
Zhang Z, Schwartz S, Wagner L and Miller W. A greedy algorithm for aligning DNA sequences. J Comput Biol. 2000;7(1-2):203-214.
Zou H, Chen Y, Duan Z, Zhang H and Pan C. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. J Viral Hepat. 2012;19(2):e18-25.